A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma

Disease Markers

Volumn 17, Issue 3, 2001, Pages 179-189

  Ruilova Zavgorodniy, V A ^a   Vereshchagin, A K ^a   Paraschuk, D Y ^a   Kobryanskii, V M ^b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b SEMENOV INSTITUTE OF CHEMICAL PHYSICS   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; GLYCAN; IMMUNOGLOBULIN G; OLIGOSACCHARIDE; POLYPEPTIDE;

AMINO ACID SEQUENCE; CARBOHYDRATE ANALYSIS; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MASS SPECTROMETRY; OPTICAL RESOLUTION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MODIFICATION; REPRODUCIBILITY; REVIEW; RNA TRANSLATION; STANDARDIZATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0035668456     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2001/963023     Document Type: Review

References (56)

1. NIH conference
2. Epidemiology of primary liver cancer
3. Estimates of the worldwide incidence of 25 major cancers in 1990
4. Hepatitis B virus. The major etiology of hepatocellular carcinoma
5. Rising incidence of hepatocellular carcinoma in the United States
6. Changing incidence of hepatocellular carcinoma in Japan
7. Increase in primary liver cancer in the UK
8. Trends in primary liver cancer
9. The treatment of chronic viral hepatitis
10. Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis
11. HCV-associated hepatocellular carcinoma without cirrhosis
12. Hepatitis C virus and hepatocellular carcinoma
13. Epidemiology of hepatitis C
14. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
15. Emerging therapies for viral hepatitis
16. Hepatocellular carcinoma: The clinical problem
17. Hepatitis B virus (HBV) and hepatocellular carcinoma. HBV DNA status and its implications
18. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma
19. Serum alpha fetoprotein heterogeneity as a means of differentiating between primary hepatocellular carcinoma and hepatic secondaries
20. The role of liver biopsy in chronic hepatitis C
21. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation
22. Alpha-fetoprotein in the woodchuck model for hepadnavirus infection and disease: Normal physiological patterns and responses to woodchuck hepatitis virus infection and hepatocellular carcinoma
23. Altered glycosylation of alpha-fetoprotein in hepadnavirus-induced hepatocellular carcinoma of the woodchuck
24. The fucosylation index of alpha-fetoprotein as a possible prognostic indicator for patients with hepatocellular carcinoma
25. The transcriptional program in the response of human fibroblasts to serum
26. Analyzing uncharted transcriptomes with SAGE
27. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
28. Proteome research: Complementarity and limitations with respect to the RNA and DNA worlds
29. The current state of two-dimensional electrophoresis with immobilized pH gradients
30. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: Current status
31. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients
32. Advances in protein solubilisation for two-dimensional electrophoresis
33. A thousand points of light: The application of fluorescence detection technologies to two-dimensional gel electrophoresis and proteomics
34. Postelectrophoretic staining of proteins separated by two-dimensional gel electrophoresis using SYPRO dyes
35. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry
36. Biosensor chip mass spectrometry: A chip-based proteomics approach
37. Capillary isoelectric focuing and isoelectric buffers: An evolving scenario
38. Isoelectric focusing nonporous RP HPLC: A two-dimensional liquid-phase separation method for mapping of cellular proteins with identification using MALDI-TOF mass spectrometry
39. High resolution two-dimensional electrophoresis of proteins
40. Towards higher resolution: Two-dimensional electrophoresis of Saccharomyces cerevisiae proteins using overlapping narrow immobilized pH gradients
41. Towards high performance two-dimensional gel electrophoresis using ultra-zoomgels
42. Casting immobilized pH gradients (IPGs)
43. Why mammalian cell surface proteins are glycoproteins
44. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database
45. Glycoprotein glycosylationand cancer progression
46. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism
47. Perspectives on the significance of altered glycosylation of glycoproteins in cancer
48. A retrospective and prospective view of glycopathology
49. Pathways of O-glycan biosynthesis in cancer cells
50. Clinical aspects of altered glycosylation of glycoproteins in cancer
51. Carbohydrate-based measurements on alpa-fetoprotein as a possible indicator for patients with hepatocellualr carcinoma
52. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles
53. Biochemical aspects of alpha-L-fucosidase in hepatocellular carcinoma
54. Altered glycosylation of serum transferrin of patients with hepatocellualr carcinoma
55. Structure of asparagine-linked sugar-chains in the major polypeptide of hepatitis B surface antigen